MATLIN DAVID J 4

What Happened David J. Matlin, a director of TriSalus Life Sciences, was granted a total of 107,669 shares on May 14, 2026 via equity awards reported as acquisitions at $0.00 per share (total reported value $0). The grants break down as: 28,201 RSUs (F1), 23,065 RSUs elected in lieu of board cash retainer (F2), and 56,403 shares reported as a derivative/option-type award (F3). These are awards/vesting grants rather than open-market purchases or sales.

Key Details

• Transaction date: May 14, 2026; filing date: May 15, 2026 (timely).
• Reported price: $0.00 per share; reported total value: $0.
• Grant breakdown: 28,201 RSUs (F1); 23,065 Retainer RSUs (F2); 56,403 derivative/option-type award (F3). Total = 107,669 shares.
• Vesting: F1 RSUs vest in full on May 14, 2027 (one-year cliff). F2 Retainer RSUs vest quarterly in equal one‑third installments through the remainder of 2026. F3 derivative/option fully vests on May 14, 2027 (one-year anniversary).
• Shares owned after the transactions: not specified in the filing.
• No 10b5-1 plan, tax-withholding sale, or late filing noted in the disclosure.

Context These grants are typical director compensation (including an election to take retainer pay as RSUs) and represent future potential equity subject to continued service and vesting schedules. They do not involve immediate cash purchases or sales, and do not by themselves indicate buying or selling sentiment—vesting schedules determine when the shares may be issued.